Eton Pharmaceuticals, Inc. cash flow to debt ratio of 33.93% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Eton Pharmaceuticals, Inc.'s free cash flow has increased 980.70% from $943.00K last year to $10.19M, signaling increasing performance

Eton Pharmaceuticals, Inc.'s debt to equity ratio is 0.40, which means that the company's assets are healthy financed, signaling financial stability.

Eton Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 1.23 last year to 0.40 today, signaling strengthened financials

Eton Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 1.19x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Eton Pharmaceuticals, Inc.'s interest coverage ratio is 0.73, which means that the company struggles to meet interest obligations, signaling financial risk.

Eton Pharmaceuticals, Inc.'s profit margin has increased (-82.69%) in the last year from -9.80% to -1.70%, signaling increasing performance

Eton Pharmaceuticals, Inc.'s short-term assets of $60.58M exceed its short-term liabilities of $38.49M

Eton Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Eton Pharmaceuticals, Inc.'s return on equity of -5.68%, is lower than 15.00%, indicating bad performance

Eton Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Eton Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Eton Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Eton Pharmaceuticals, Inc. has a free cash flow yield of 0.85%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Eton Pharmaceuticals, Inc.'s yearly earnings has decreased 20.35% since last year from $-3.82M to $-4.60M, signaling decreasing performance

Eton Pharmaceuticals, Inc.'s yearly revenue has increased 104.94% since last year from $39.01M to $79.95M, signaling increasing performance

ROIC 3.10% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Eton Pharmaceuticals, Inc.'s 3-year revenue CAGR of 55.53% is positive, indicating growing revenue over the past 3 years

Eton Pharmaceuticals, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Eton Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Eton Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eton Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eton Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.87 based on EBITDA multiple model

Eton Pharmaceuticals, Inc. has an EV/EBITDA ratio of 281.53x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Eton Pharmaceuticals, Inc. is overvalued relative to its fair value price of -3.83 based on Earnings Fair Value model

Eton Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eton Pharmaceuticals, Inc. has a price-to-book ratio of 38.92x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Eton Pharmaceuticals, Inc. has a price-to-sales ratio of 13.71x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue